Aliases & Classifications for Liposarcoma

MalaCards integrated aliases for Liposarcoma:

Name: Liposarcoma 12 72 49 51 41 14 69

Classifications:



Summaries for Liposarcoma

NIH Rare Diseases : 49 Liposarcoma is a tumor that arises from fat tissue. This tumor often occurs in the thigh, legs, behind the knee, or in the abdomen, but it can be found in other parts of the body, in the retroperitoneum; and, less often, in the head and neck area. Their primary occurrence in the skin is rare. Because a liposarcoma may grow into surrounding tissues or organs, it is considered a malignant tumor. The World Health Organization classification of soft tissue tumors recognizes 5 types of liposarcomas: Well differentiated, which includes the adipocytic, sclerosing, and inflammatory subtypes; dedifferentiated; myxoid; round cell; and pleomorphic. Most patients with liposarcoma have no symptoms until the tumor is large and invades the neighboring organs or tissues, causing tenderness, pain, or functional problems. Although surgical removal of the tumor is the curative treatment, some patients may benefit from chemotherapy and radiation. Most patients with liposarcoma have no symptoms until the tumor is large and impinges on neighboring structures, causing tenderness, pain, or functional disturbances. In the retroperitoneal area, where liposarcoma is detected at a late stage, the tumor may grow to a substantial size, weighing several pounds at the time of diagnosis. In general, liposarcoma grows silently, and the patient's estimation of the clinical duration is often unreliable. The patient eventually becomes aware of a swelling or a mass and reports this finding to the physician. Patients may report the following: Associated episode of trauma to the region containing the mass Painful swelling (occurs in one third of cases for as long as 6 mo) Decreased function (ie, range of motion) Numbness Enlargement of varicose veins Fatigue Abdominal pain Weight loss Nausea Vomiting  Last updated: 6/23/2016

MalaCards based summary : Liposarcoma is related to pleomorphic liposarcoma and myxoid liposarcoma, and has symptoms including abnormality of the kidney, subcutaneous nodule and weight loss. An important gene associated with Liposarcoma is FUS (FUS RNA Binding Protein), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Endometrial cancer. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include adipocyte, t cells and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A lipomatous cancer that arises in fat cells in deep soft tissue retroperitoneum.

Wikipedia : 72 Liposarcoma is a cancer that arises in fat cells in deep soft tissue, such as that inside the thigh or... more...

Related Diseases for Liposarcoma

Diseases in the Liposarcoma family:

Adult Liposarcoma Inflammatory Liposarcoma

Diseases related to Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 317)
# Related Disease Score Top Affiliating Genes
1 pleomorphic liposarcoma 33.4 CDKN2A DES MDM2 VIM
2 myxoid liposarcoma 33.2 CDK4 DDIT3 EWSR1 FUS HMGA2 LRP1
3 dedifferentiated liposarcoma 33.0 CDK4 CDKN2A DES HMGA2 MDM2 TP53
4 well-differentiated liposarcoma 32.9 CDK4 CDKN2A HMGA2 MDM2 TSPAN31
5 sclerosing liposarcoma 32.5 CD34 FUS MB MDM2 TP53
6 spindle cell liposarcoma 32.5 CALB2 CD34 CDK4 DDIT3 MDM2
7 mixed liposarcoma 32.4 CD34 CDK4 DDIT3 FUS MB MDM2
8 lipomatosis, multiple 30.8 CDK4 DES FUS HMGA2 MDM2
9 sarcoma 30.5 EWSR1 FUS MDM2 RB1 TP53
10 soft tissue sarcoma 30.5 EWSR1 MDM2 TP53
11 hemangiopericytoma, malignant 30.4 DES MDM2 VIM
12 fibrous histiocytoma 30.3 DES EWSR1 FUS VIM
13 li-fraumeni syndrome 30.2 CDKN2A MDM2 TP53
14 angiolipoma 30.2 DES VIM
15 atypical lipomatous tumor 30.1 CDK4 CDKN2A FUS HMGA2 MDM2 TSPAN31
16 mesenchymoma 30.0 DES HMGA2 MB MDM2
17 conventional central osteosarcoma 30.0 EWSR1 MDM2
18 retroperitoneal fibrosis 29.9 MDM2 VIM
19 cutaneous leiomyosarcoma 29.9 DES VIM
20 chondroid lipoma 29.9 CDK4 DDIT3 FUS MDM2
21 myxofibrosarcoma 29.8 DES FUS
22 inflammatory myofibroblastic tumor 29.8 DES MDM2 TP53 VIM
23 leiomyoma 29.7 CD34 DES HMGA2
24 leiomyosarcoma 29.6 CDK4 DES MB MDM2 TP53 VIM
25 pleomorphic adenoma 29.6 HMGA2 MDM2 TP53 VIM
26 osteogenic sarcoma 29.6 CDK4 MDM2 RB1 TP53
27 spindle cell lipoma 29.6 CDK4 DES MDM2 RB1 VIM
28 rhabdomyosarcoma 29.4 CDK4 DES EWSR1 MB MDM2 TP53
29 malignant mesenchymoma 29.4 CDK4 DES EWSR1 MB MDM2 TP53
30 retinoblastoma 29.4 CDK4 CDKN2A MDM2 RB1 TP53
31 leukemia, acute myeloid 29.3 CD34 CDKN2A MDM2 TP53
32 histiocytoma 29.3 CDK4 EWSR1 FUS MB MDM2 TP53
33 pleomorphic lipoma 29.2 CALB2 CD34 CDK4 HMGA2 MDM2
34 sarcoma, synovial 29.2 CALB2 DES HMGA2 MDM2 VIM
35 malignant peripheral nerve sheath tumor 29.0 CD34 CDK4 CDKN2A MDM2 TP53 VIM
36 mediastinum liposarcoma 12.2
37 larynx liposarcoma 12.1
38 kidney liposarcoma 12.1
39 retroperitoneal liposarcoma 12.1
40 gastric liposarcoma 12.0
41 cellular myxoid liposarcoma 12.0
42 inflammatory liposarcoma 12.0
43 liposarcoma of the ovary 12.0
44 breast liposarcoma 12.0
45 myxoid liposarcoma of the ovary 12.0
46 esophagus liposarcoma 12.0
47 liposarcoma of bone 11.9
48 vulvar liposarcoma 11.9
49 cutaneous liposarcoma 11.8
50 adult liposarcoma 11.8

Graphical network of the top 20 diseases related to Liposarcoma:



Diseases related to Liposarcoma

Symptoms & Phenotypes for Liposarcoma

Human phenotypes related to Liposarcoma:

31 (show all 9)
# Description HPO Frequency HPO Source Accession
1 abnormality of the kidney 31 occasional (7.5%) HP:0000077
2 subcutaneous nodule 31 hallmark (90%) HP:0001482
3 weight loss 31 occasional (7.5%) HP:0001824
4 nausea and vomiting 31 occasional (7.5%) HP:0002017
5 abdominal pain 31 occasional (7.5%) HP:0002027
6 varicose veins 31 occasional (7.5%) HP:0002619
7 paresthesia 31 occasional (7.5%) HP:0003401
8 fatigue 31 occasional (7.5%) HP:0012378
9 sarcoma 31 hallmark (90%) HP:0100242

GenomeRNAi Phenotypes related to Liposarcoma according to GeneCards Suite gene sharing:

25 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.78 VIM
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.78 FUS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-12 9.78 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.78 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.78 TP53
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.78 VIM
7 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.78 FUS
8 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.78 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.78 VIM
10 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.78 VIM
11 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.78 VIM
12 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.78 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.78 VIM FUS PPARG TP53
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 FUS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.78 VIM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.78 FUS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.78 VIM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.78 TP53
19 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.78 PPARG
20 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.78 FUS TP53
21 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.78 FUS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.78 VIM
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.78 FUS
24 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.78 FUS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 VIM

MGI Mouse Phenotypes related to Liposarcoma:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 CDKN2A LRP1 CD34 CDK4 DDIT3 DES
2 behavior/neurological MP:0005386 10.33 DES CALB2 CDKN2A DDIT3 CDK4 MDM2
3 cardiovascular system MP:0005385 10.31 DES CDKN2A CDK4 DDIT3 MB MDM2
4 homeostasis/metabolism MP:0005376 10.3 DES CDKN2A CD34 DDIT3 CDK4 MB
5 hematopoietic system MP:0005397 10.29 CDKN2A LRP1 CD34 CDK4 DDIT3 MDM2
6 growth/size/body region MP:0005378 10.24 CDK4 CDKN2A DDIT3 MB PPARG MDM2
7 embryo MP:0005380 10.21 CDKN2A CDK4 MB MDM2 RB1 LRP1
8 immune system MP:0005387 10.17 CDKN2A CD34 DDIT3 CDK4 PPARG MDM2
9 integument MP:0010771 10.06 CDKN2A CD34 CDK4 MDM2 RB1 LRP1
10 liver/biliary system MP:0005370 10.02 CDKN2A CDK4 DDIT3 MDM2 RB1 LRP1
11 muscle MP:0005369 10.02 DES CDKN2A LRP1 CDK4 MDM2 RB1
12 nervous system MP:0003631 9.9 CALB2 CDKN2A DDIT3 CDK4 PPARG MDM2
13 neoplasm MP:0002006 9.86 CDKN2A CD34 DDIT3 CDK4 MDM2 RB1
14 pigmentation MP:0001186 9.35 CDK4 CDKN2A MDM2 TP53 RB1
15 reproductive system MP:0005389 9.28 CDK4 CDKN2A PPARG MDM2 LRP1 TP53

Drugs & Therapeutics for Liposarcoma

Drugs for Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
6
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
7
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
8
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
10
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
11
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
12
Vincristine Approved, Investigational Phase 3,Phase 2 2068-78-2, 57-22-7 5978
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
17
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2 114977-28-5 148124 9877265
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
23 Liver Extracts Phase 3
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
25 Etoposide phosphate Phase 3,Phase 2
26 Anti-Infective Agents Phase 3,Phase 2,Phase 1
27 Antimitotic Agents Phase 3,Phase 2
28 Antirheumatic Agents Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
31 Antimetabolites Phase 3,Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
33 Antiviral Agents Phase 3,Phase 2,Phase 1
34 Gastrointestinal Agents Phase 3,Phase 2
35 Pharmaceutical Solutions Phase 3
36 Anti-Allergic Agents Phase 3
37 Antipruritics Phase 3
38 Dermatologic Agents Phase 3
39 Histamine Antagonists Phase 3
40 Histamine H1 Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Neurotransmitter Agents Phase 3
43
Serotonin Phase 3 50-67-9 5202
44 Serotonin Agents Phase 3
45 Serotonin Antagonists Phase 3
46
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
47
Palbociclib Approved, Investigational Phase 2,Phase 1 571190-30-2 5330286 11431660 5005498
48
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
49
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
50
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102

Interventional clinical trials:

(show top 50) (show all 117)

# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
3 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
4 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
6 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
8 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
9 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
10 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
11 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
12 Selinexor in Advanced Liposarcoma Recruiting NCT02606461 Phase 2, Phase 3 Selinexor;Placebo
13 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
14 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
15 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Recruiting NCT01344018 Phase 3
16 A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Active, not recruiting NCT01692678 Phase 3 Trabectedin;Dacarbazine
17 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
18 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
20 Brostallicin Clinical Trial for Myxoid Liposarcoma Unknown status NCT00633165 Phase 2 Brostallicin
21 Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial Unknown status NCT01692496 Phase 2 Pazopanib
22 Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
23 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
24 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
25 Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Completed NCT01506596 Phase 2 pazopanib
26 PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma Completed NCT01209598 Phase 2 Palbociclib 200mg;Palbociclib 125mg
27 Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma Completed NCT00579501 Phase 2 Trabectedin;Dexamethasone
28 Rosiglitazone in Treating Patients With Liposarcoma Completed NCT00004180 Phase 2 rosiglitazone maleate
29 Troglitazone in Treating Patients With Liposarcoma Completed NCT00003058 Phase 2 troglitazone
30 A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
31 Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma Completed NCT00400569 Phase 2 Sunitinib Malate (SU011248)
32 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
33 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
34 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
35 Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) Completed NCT00093080 Phase 2 ridaforolimus
36 Bevacizumab and Radiation Therapy for Sarcomas Completed NCT00356031 Phase 2 Bevacizumab
37 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
38 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
39 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
40 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
41 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
42 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
43 S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas Completed NCT00217620 Phase 2 sorafenib
44 Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00064220 Phase 2 soblidotin
45 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
46 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
47 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
48 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
49 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
50 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate

Search NIH Clinical Center for Liposarcoma

Cochrane evidence based reviews: liposarcoma

Genetic Tests for Liposarcoma

Anatomical Context for Liposarcoma

MalaCards organs/tissues related to Liposarcoma:

38
Adipocyte, T Cells, Bone, Skin, Liver, Breast, Colon

Publications for Liposarcoma

Articles related to Liposarcoma:

(show top 50) (show all 1358)
# Title Authors Year
1
Extended surgery using anterior mediastinal tracheostomy for recurrent mediastinal liposarcoma. ( 29415198 )
2018
2
A retrospective, single-center cohort study on 65 patients with primary retroperitoneal liposarcoma. ( 29434876 )
2018
3
FUS-CHOP Promotes Invasion in Myxoid Liposarcoma through a SRC/FAK/RHO/ROCK-Dependent Pathway. ( 29190494 )
2018
4
Acute haemorrhage from a retroperitoneal liposarcoma: a rare presentation. ( 29437802 )
2018
5
Clarifying the Distinction Between Malignant Peripheral Nerve Sheath Tumor and Dedifferentiated Liposarcoma: A Critical Reappraisal of the Diagnostic Utility of MDM2 and H3K27me3 Status. ( 29309298 )
2018
6
Mosaic-pattern dedifferentiation in liposarcoma and chondrosarcoma: imaging features of an uncommon form of dedifferentiation. ( 29362843 )
2018
7
A dedifferentiated liposarcoma with inflammatory myofibroblastic tumor-like features. ( 29446522 )
2018
8
Surgery for Abdominal Well-Differentiated Liposarcoma. ( 29335908 )
2018
9
The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients. ( 29280411 )
2018
10
Pleomorphic liposarcoma of bone: a rare primary malignant bone tumour. ( 29449935 )
2018
11
Well-Differentiated Liposarcoma (Atypical Lipomatous Tumor) Presenting as an Esophageal Polyp. ( 29349606 )
2018
12
Primary Breast Atypical Lipomatous Tumor/ Well-Differentiated Liposarcoma and Dedifferentiated Liposarcoma. ( 29372852 )
2018
13
Lipoblastoma-like Tumor of the Vulva, an Important Benign Mimic of Myxoid Liposarcoma. ( 29300200 )
2018
14
Dedifferentiated liposarcoma composed predominantly of rhabdoid/epithelioid cells: a frequently misdiagnosed highly aggressive variant. ( 29307627 )
2018
15
Amplification of FRS2 in atypical lipomatous tumour/well -differentiated liposarcoma and dedifferentiated liposarcoma: a clinicopathological and genetic study of 146 cases. ( 29368794 )
2018
16
Hibernation of masses suspected to be remnant tumors after surgical resection of retroperitoneal liposarcoma is related to improved overall survival. ( 29352382 )
2018
17
Early detection of metastases using whole-body MRI for initial staging and routine follow-up of myxoid liposarcoma. ( 29275455 )
2018
18
PRG4 expression in myxoid liposarcoma maintains tumor cell growth through suppression of an antitumor cytokine IL-24. ( 28192118 )
2017
19
Incidentally discovered well-differentiated retroperitoneal liposarcoma with inguinal canal herniation: report of 2 cases. ( 28491177 )
2017
20
Myxoid liposarcoma with cartilaginous differentiation showing<i>DDIT3</i>rearrangement. ( 29181103 )
2017
21
Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma. ( 28099935 )
2017
22
Eribulin: an effective therapeutic option in liposarcoma. ( 28890295 )
2017
23
Paraneoplastic Cerebellar Degeneration Associated with Pelvic Liposarcoma: A Rare Case Report. ( 28092914 )
2017
24
miR-193b-regulated signaling networks serve as tumor suppressors in liposarcoma and promote adipogenesis in adipose-derived stem cells. ( 28882999 )
2017
25
FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma. ( 28637688 )
2017
26
Well-differentiated Liposarcoma in a Bonnet Macaque (<i>Macaca radiata</i>). ( 28381318 )
2017
27
MRI characteristics associated with high-grade myxoid liposarcoma. ( 28256200 )
2017
28
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen. ( 28774898 )
2017
29
Extensive left ventricular, pulmonary artery, and pericardial metastasis from myxoid liposarcoma 16 years after the initial detection of the primary tumour: a case report and review of the literature. ( 28866706 )
2017
30
Primary atypical lipomatous tumor/well-differentiated liposarcoma (ALT/WDL) of the breast. ( 28845581 )
2017
31
Gastric liposarcoma resected by laparoscopic total gastrectomy to achieve a wide surgical margin. ( 29212871 )
2017
32
Systemic Therapy in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma. ( 29250486 )
2017
33
Malignant solitary fibrous tumour of the kidney with lymph node and liver metastases: beware of STAT6 expression in dedifferentiated liposarcoma with a solitary fibrous tumour-like morphology: author reply. ( 28838615 )
2017
34
p16 Immunohistochemistry is Less Useful Than MDM2 and CDK4 to Distinguish Dedifferentiated Liposarcomas From Other Retroperitoneal Mimics. ( 26509911 )
2017
35
Endoscopic submucosal dissection of a huge esophageal atypical lipomatous tumor (well-differentiated liposarcoma) with a 4-year recurrence-free survival. ( 28719927 )
2017
36
Dedifferentiated Liposarcoma of the Retroperitoneum With Heterologous Osteosarcomatous Differentiation and a Striking Aneurysmal Bone Cyst-Like Morphology. ( 28193096 )
2017
37
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. ( 28854066 )
2017
38
Retroperitoneal Liposarcoma: An Aggressive Strategy to Maximize Disease Control. ( 28463147 )
2017
39
Osteogenic differentiation in dedifferentiated liposarcoma: a study of 36 cases in comparison to the cases without ossification. ( 29076540 )
2017
40
Effective apatinib treatment of pleomorphic liposarcoma: A case report. ( 28816958 )
2017
41
Dedifferentiated liposarcoma of the lower extremity with low-grade dedifferentiation and low-grade osteosarcomatous component. ( 27909788 )
2017
42
Well-differentiated liposarcoma with chondroid metaplasia in the auricle of a dog. ( 28603215 )
2017
43
Unusual subcutaneous invasion of myxoid liposarcoma. ( 29168208 )
2017
44
High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. ( 28947876 )
2017
45
Giant retroperitoneal dedifferentiated liposarcoma. ( 28098568 )
2017
46
Neuropraxia following resection of a retroperitoneal liposarcoma. ( 28601782 )
2017
47
Dedifferentiated primary mediastinal liposarcoma mimicking a thymic tumor. ( 29449733 )
2017
48
Resection of giant mediastinal liposarcoma via 'a8L shape' incision. ( 28044001 )
2017
49
Successful surgical treatment for huge retroperitoneal liposarcoma involving the pancreas, right kidney, abdominal aorta and inferior vena cava. ( 29423155 )
2017
50
Dedifferentiated Liposarcoma Mimicking a Primary Colon Mass. ( 28950740 )
2017

Variations for Liposarcoma

Cosmic variations for Liposarcoma:

9 (show all 36)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM11245 TP53 soft tissue,fat,liposarcoma,well differentiated c.430C>T p.Q144* 12
2 COSM44723 TP53 soft tissue,fat,liposarcoma,well differentiated c.674T>C p.V225A 12
3 COSM10646 TP53 soft tissue,fat,liposarcoma,well differentiated c.725G>A p.C242Y 12
4 COSM44094 TP53 soft tissue,fat,liposarcoma,well differentiated c.716A>G p.N239S 12
5 COSM6901 TP53 soft tissue,fat,liposarcoma,well differentiated c.559+1G>A p.? 12
6 COSM44112 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.640C>T p.H214Y 12
7 COSM43663 TP53 soft tissue,fat,liposarcoma,well differentiated c.826G>C p.A276P 12
8 COSM10941 TP53 soft tissue,fat,liposarcoma,well differentiated c.730G>A p.G244S 12
9 COSM11333 TP53 soft tissue,fat,liposarcoma,myxoid-round cell c.499C>T p.Q167* 12
10 COSM44512 TP53 soft tissue,fat,liposarcoma,well differentiated c.740A>G p.N247S 12
11 COSM10647 TP53 soft tissue,fat,liposarcoma,pleomorphic c.404G>T p.C135F 12
12 COSM11059 TP53 soft tissue,fat,liposarcoma,well differentiated c.713G>A p.C238Y 12
13 COSM10654 TP53 soft tissue,fat,liposarcoma,well differentiated c.637C>T p.R213* 12
14 COSM1651764 RB1 soft tissue,fat,liposarcoma,pleomorphic c.1818T>A p.Y606* 12
15 COSM775 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.3140A>G p.H1047R 12
16 COSM763 PIK3CA soft tissue,fat,liposarcoma,myxoid-round cell c.1633G>A p.E545K 12
17 COSM12458 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1634A>C p.E545A 12
18 COSM760 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1624G>A p.E542K 12
19 COSM21467 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1612G>A p.D538N 12
20 COSM25083 PIK3CA soft tissue,fat,liposarcoma,well differentiated c.1627A>G p.I543V 12
21 COSM24452 NF1 soft tissue,fat,liposarcoma,pleomorphic c.1105C>T p.Q369* 12
22 COSM28019 NF1 soft tissue,fat,liposarcoma,pleomorphic c.4006C>T p.Q1336* 12
23 COSM517 KRAS soft tissue,fat,liposarcoma,myxoid-round cell c.34G>A p.G12S 12
24 COSM532 KRAS soft tissue,fat,liposarcoma,well differentiated c.38G>A p.G13D 12
25 COSM1290 KIT soft tissue,fat,liposarcoma,well differentiated c.1727T>C p.L576P 12
26 COSM1651756 KIT soft tissue,fat,liposarcoma,myxoid-round cell c.2334G>C p.K778N 12
27 COSM487 HRAS soft tissue,fat,liposarcoma,well differentiated c.37G>A p.G13S 12
28 COSM480 HRAS soft tissue,fat,liposarcoma,well differentiated c.34G>A p.G12S 12
29 COSM720 FGFR3 soft tissue,fat,liposarcoma,well differentiated c.1949A>T p.K650M 12
30 COSM601 FGFR1 soft tissue,fat,liposarcoma,well differentiated c.374C>T p.S125L 12
31 COSM5743 CTNNB1 soft tissue,fat,liposarcoma,well differentiated c.117C>T p.A39A 12
32 COSM5708 CTNNB1 soft tissue,fat,liposarcoma,well differentiated c.119C>T p.T40I 12
33 COSM5676 CTNNB1 soft tissue,fat,liposarcoma,well differentiated c.122C>T p.T41I 12
34 COSM476 BRAF soft tissue,fat,liposarcoma,well differentiated c.1799T>A p.V600E 12
35 COSM1745010 MYOD1 soft tissue,upper leg,rhabdomyosarcoma,sclerosing c.365T>G p.L122R 4
36 COSM483 HRAS soft tissue,upper leg,malignant fibrous histiocytoma-pleomorphic sarcoma,myxoid c.35G>T p.G12V 4

Copy number variations for Liposarcoma from CNVD:

7 (show all 36)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13334 1 1 124300000 Gain Liposarcoma
2 16445 1 124300000 247249719 Loss Liposarcoma
3 20078 1 15300000 163800000 Amplification COAS1 Liposarcoma
4 20079 1 15300000 163800000 Amplification COAS2 Liposarcoma
5 20080 1 15300000 163800000 Amplification COAS3 Liposarcoma
6 20084 1 15300000 212100000 Gain Liposarcoma
7 42815 10 40300000 135374737 Loss Liposarcoma
8 55437 11 52900000 134452384 Loss Liposarcoma
9 61489 12 1 14800000 Loss Liposarcoma
10 67172 12 37282278 37312244 Amplified CHOP Liposarcoma
11 67787 12 44600000 69800000 Gain CDK4 liposarcomas
12 67788 12 44600000 69800000 Gain HMGA2 liposarcomas
13 67789 12 44600000 69800000 Gain MDM2 liposarcomas
14 69651 12 56140200 56152312 Amplified GLI1 Liposarcoma
15 69861 12 56374152 56401607 Amplified OS9 Liposarcoma
16 69873 12 56425050 56428293 Amplified TSPAN31 Liposarcoma
17 69880 12 56428269 56432431 Amplified CDK4 Liposarcoma
18 70737 12 64503703 64646338 Amplified HMGA2 Liposarcoma
19 71088 12 67488246 67520481 Amplified MDM2 Liposarcoma
20 77049 13 39500000 52200000 Loss Liposarcoma
21 77649 13 46200000 52200000 Deletion RB1 Liposarcoma
22 78496 13 52200000 114142980 Loss Liposarcoma
23 106733 17 1 11200000 Deletion Liposarcoma
24 108852 17 23200000 28800000 Deletion Liposarcoma
25 139560 2 183406981 183439743 Amplified OS1 Liposarcoma
26 149783 2 93300000 242951149 Gain Liposarcoma
27 149786 2 93300000 242951149 Loss Liposarcoma
28 166153 3 1 91700000 Gain Liposarcoma
29 166161 3 1 91700000 Loss Liposarcoma
30 179460 3 91700000 199501827 Gain Liposarcoma
31 187537 4 50700000 191273063 Loss Liposarcoma
32 191663 5 1 45800000 Gain Liposarcoma
33 200009 5 47700000 180857866 Gain Liposarcoma
34 210239 6 29900000 45200000 Gain Liposarcoma
35 217105 7 1 59100000 Gain Liposarcoma
36 225569 7 47600000 107200000 Gain Liposarcoma

Expression for Liposarcoma

Search GEO for disease gene expression data for Liposarcoma.

Pathways for Liposarcoma

Pathways related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.09 CDK4 CDKN2A HMGA2 MDM2 RB1 TP53
2
Show member pathways
13.01 CDK4 CDKN2A MDM2 PPARG RB1 TP53
3 12.77 CDK4 CDKN2A MDM2 PPARG RB1 TP53
4
Show member pathways
12.52 CDK4 CDKN2A MDM2 RB1 TP53
5
Show member pathways
12.51 CDK4 CDKN2A MDM2 RB1 TP53
6 12.45 CDKN2A HMGA2 MDM2 TP53 VIM
7 12.38 CDK4 RB1 TP53 VIM
8 12.37 CDK4 CDKN2A RB1 TP53
9 12.35 CDK4 CDKN2A MDM2 RB1 TP53 VIM
10
Show member pathways
12.31 CDK4 CDKN2A RB1 TP53
11
Show member pathways
12.3 CDK4 CDKN2A MDM2 RB1 TP53
12 12.28 CDK4 CDKN2A MDM2 RB1 TP53
13 12.26 MDM2 RB1 TP53 VIM
14 12.22 DDIT3 EWSR1 FUS YBX1
15
Show member pathways
12.21 CDK4 MDM2 RB1 TP53
16 12.18 CDK4 CDKN2A MDM2 RB1 TP53
17 12.1 CDK4 MDM2 RB1 TP53
18 12.06 CDK4 CDKN2A MDM2 RB1 TP53
19
Show member pathways
12.02 CDK4 CDKN2A MDM2 RB1 TP53
20 12.01 CDKN2A MDM2 RB1 TP53
21 12.01 CDK4 CDKN2A MDM2 TP53
22 11.94 CDK4 RB1 TP53 VIM
23 11.87 CDKN2A MDM2 RB1 TP53
24 11.83 CD34 DES PPARG
25 11.82 CDK4 RB1 TP53
26 11.76 CDK4 CDKN2A MDM2 RB1 TP53
27 11.74 CDK4 MDM2 RB1 TP53
28 11.7 CDKN2A MDM2 TP53
29
Show member pathways
11.69 CDKN2A MDM2 TP53
30 11.56 MDM2 PPARG RB1
31 11.54 CDKN2A MDM2 TP53
32 11.5 CDKN2A RB1 TP53
33 11.44 DDIT3 EWSR1 FUS HMGA2 MDM2 PPARG
34 11.42 CDK4 MDM2 TP53
35 11.42 CDK4 CDKN2A MDM2 RB1 TP53
36 11.33 CDK4 MDM2 RB1 TP53
37 11.06 CDK4 CDKN2A MDM2 TP53
38
Show member pathways
11.03 CDKN2A MDM2 TP53
39 10.6 CDKN2A MDM2 RB1 TP53

GO Terms for Liposarcoma

Cellular components related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.85 CDK4 CDKN2A EWSR1 LRP1 MDM2 TP53
2 cytoplasm GO:0005737 9.83 CALB2 CD34 CDK4 CDKN2A DDIT3 DES
3 senescence-associated heterochromatin focus GO:0035985 9.26 CDKN2A HMGA2
4 chromatin GO:0000785 8.92 CDK4 HMGA2 RB1 TP53
5 cytosol GO:0005829 10.13 CALB2 CDK4 CDKN2A DDIT3 DES LRP1
6 nucleoplasm GO:0005654 10.1 CDK4 CDKN2A DDIT3 FUS HMGA2 MDM2
7 nucleus GO:0005634 10.03 CALB2 CDK4 CDKN2A DDIT3 DES EWSR1

Biological processes related to Liposarcoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.97 CDK4 CDKN2A DDIT3 HMGA2 RB1 TP53
2 positive regulation of transcription, DNA-templated GO:0045893 9.91 CDKN2A DDIT3 HMGA2 PPARG RB1 TP53
3 positive regulation of apoptotic process GO:0043065 9.85 CDK4 CDKN2A HMGA2 PPARG TP53
4 G1/S transition of mitotic cell cycle GO:0000082 9.78 CDK4 CDKN2A RB1
5 Ras protein signal transduction GO:0007265 9.71 CDKN2A RB1 TP53
6 cell cycle arrest GO:0007050 9.71 CDKN2A DDIT3 RB1 TP53
7 negative regulation of neuron projection development GO:0010977 9.7 LRP1 MDM2 VIM
8 negative regulation of transcription by RNA polymerase II GO:0000122 9.7 DDIT3 HMGA2 MDM2 PPARG RB1 TP53
9 positive regulation of cellular senescence GO:2000774 9.6 CDKN2A HMGA2
10 replicative senescence GO:0090399 9.59 CDKN2A TP53
11 response to caffeine GO:0031000 9.58 PPARG TP53
12 ER overload response GO:0006983 9.58 DDIT3 TP53
13 positive regulation of transcription from RNA polymerase II promoter in response to endoplasmic reticulum stress GO:1990440 9.57 DDIT3 TP53
14 negative regulation of telomerase activity GO:0051974 9.56 PPARG TP53
15 amyloid fibril formation GO:1990000 9.55 CDKN2A MDM2
16 positive regulation of cell cycle GO:0045787 9.54 CDK4 MDM2 TP53
17 enucleate erythrocyte differentiation GO:0043353 9.48 MB RB1
18 positive regulation of gene expression GO:0010628 9.43 CD34 CDKN2A HMGA2 MDM2 TP53 VIM
19 cellular response to actinomycin D GO:0072717 9.32 MDM2 TP53
20 senescence-associated heterochromatin focus assembly GO:0035986 9.26 CDKN2A HMGA2
21 negative regulation of transcription, DNA-templated GO:0045892 9.17 CDKN2A DDIT3 HMGA2 MDM2 PPARG RB1
22 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 CDKN2A DDIT3 HMGA2 PPARG RB1 TP53

Molecular functions related to Liposarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.97 CDKN2A DDIT3 FUS HMGA2 PPARG RB1
2 identical protein binding GO:0042802 9.81 DES EWSR1 FUS MDM2 PPARG RB1
3 transcription regulatory region DNA binding GO:0044212 9.67 DDIT3 HMGA2 PPARG TP53
4 enzyme binding GO:0019899 9.65 HMGA2 MDM2 PPARG RB1 TP53
5 disordered domain specific binding GO:0097718 9.26 CDKN2A MDM2 RB1 TP53
6 transcription factor binding GO:0008134 9.17 CD34 CDKN2A DDIT3 HMGA2 PPARG RB1

Sources for Liposarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....